Early Prenatal RhD Testing With Single-Assay Fetal Fraction Sequencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-invasive prenatal tests (NIPT) for determining fetal Rhesus D genotype and fraction are limited by late administration (usually after week 20), high costs, poor performance, and inability to detect RHD pseudogene, leading to unnecessary Rhogam administration and Rh sensitization risks.
Innovation Solution
A non-invasive prenatal testing methodology using next-generation sequencing and multiplex PCR to simultaneously amplify and sequence polymorphic allele loci and RhD gene locations, allowing early (week 10) fetal fraction and genotype determination, including RHDψ variants, in a single assay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If qPCR-based NIPT is administered after week 20, then the test becomes reliable, but the administration time is delayed and costs increase
Solution Approach 1:
The patent changes the detection parameters by using next-generation sequencing with multiplex PCR to simultaneously detect multiple fetal DNA markers (including RHD gene and polymorphic alleles) with higher sensitivity. This enables reliable testing at earlier gestational ages (week 10 or later) by detecting lower concentrations of fetal cfDNA that were previously undetectable with qPCR alone
Solution Approach 2:
The patent creates a multi-functional assay that simultaneously performs multiple functions: (1) determines fetal Rhesus D genotype, (2) measures fetal fraction, and (3) detects various RhD genotypes including pseudogenes. This consolidated approach improves reliability while enabling earlier administration by eliminating the need for separate tests
2Reliability
If Rhogam is administered prophylactically at week 28, then RhD sensitization is prevented, but 40% of mothers receive needlessly administered Rhogam
Solution Approach 1:
The patent performs preliminary fetal Rhesus D genotype determination at week 10 or later in pregnancy, well before the week 28 prophylactic Rhogam administration. This early detection allows clinicians to identify mothers carrying RhD-negative fetuses who do not need Rhogam, preventing unnecessary administration while ensuring timely treatment for those who need it
Solution Approach 2:
The patent enables the fetal genotype to effectively 'identify itself' through non-invasive detection of fetal DNA markers in maternal blood. The assay automatically distinguishes between RhD-positive and RhD-negative fetuses by detecting presence/absence of RHD gene sequences, allowing for automated decision-making about Rhogam necessity without additional invasive procedures
3Reliability
If standard of care protocols are followed, then RhD sensitization is prevented, but bleeding events prior to week 28 still lead to sensitization
Solution Approach 1:
The patent establishes fetal Rhesus D status at week 10 or later, creating a permanent knowledge base that guides management throughout the entire pregnancy. This preliminary determination allows for immediate adjustment of care protocols following bleeding events, eliminating the time delay inherent in waiting until week 28 for genotype information
Solution Approach 2:
The patent creates a feedback loop where early fetal genotype determination informs ongoing clinical decision-making. When bleeding events occur, the previously obtained fetal Rhesus D status provides immediate feedback to guide whether Rhogam is needed, enabling real-time adaptation of prophylaxis strategies rather than relying on fixed weekly 28 protocols
4Measurement precision
If next-generation sequencing is used for early fetal fraction and genotype determination, then detection accuracy improves, but the complexity of the assay increases
Solution Approach 1:
The patent segments the complex detection task into distinct molecular targets: (1) polymorphic allele loci for fetal fraction determination, and (2) RhD gene locations for genotype determination. By designing separate but simultaneous PCR amplification reactions for each target type, the assay achieves high measurement precision while organizing complexity into manageable, standardized modules
Solution Approach 2:
The patent merges multiple detection functions into a single integrated next-generation sequencing assay. By combining fetal fraction measurement and RhD genotype determination in one workflow, the patent achieves high precision for both measurements while reducing overall procedural complexity compared to performing separate tests sequentially
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate, low-cost, and reliable fetal Rhesus D genotype and fraction measurement, reducing no-call rates and false positives, with the potential for genetic disease detection and fetal sex determination, thus preventing unnecessary Rhogam administration.
Implementation Method 1
performing multiplex polymerase chain reaction of the cell-free DNA to simultaneously amplify polymorphic allele loci and multiple RhD gene locations
Implementation Method 2
sequencing amplified DNA; identifying and selecting polymorphic paternal alleles to obtain a fetal fraction measurement; identifying and selecting amplified RhD gene regions to obtain quantitative fetal RhD data
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A highly accurate non-invasive prenatal testing methodology that allows accurate fetal rhesus determination and fetal DNA fraction measurement in a single assay is provided. The disclosed testing may be administered as early as at week 10 of pregnancy and can be conveniently combined with prenatal genetic disease testing and detection.